Evidence map›Paper›PMID 41893160›Full record

ArticleJournal of fungi (Basel, Switzerland)2026

Novel Nitric Oxide-Releasing Formulations Show Fungicidal Potential for Superficial Dermatophyte Infection.

Aditya K Gupta, Elizabeth A Cooper, Lisa Miller, Morgan Kearl, Chris C Miller, Harmanpreet Kaur, Najmeh Dorafshanian, James Martins, Simon J L Teskey, Jeremy Road

Abstract read
In one paragraph

Article in Journal of fungi (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Aditya K GuptaMediprobe Research Inc., London, ON N5X 2P1, Canada.ORCID 0000-0002-8664-7723
Elizabeth A CooperMediprobe Research Inc., London, ON N5X 2P1, Canada.ORCID 0000-0002-1121-5619
Lisa MillerFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Morgan KearlValley Podiatry, Chilliwack, BC V2R 0J2, Canada.
Chris C MillerSaNOtize Research & Development Corp, Vancouver, BC V6P 6T3, Canada.ORCID 0000-0002-5697-2779
Harmanpreet KaurSaNOtize Research & Development Corp, Vancouver, BC V6P 6T3, Canada.
Najmeh DorafshanianSaNOtize Research & Development Corp, Vancouver, BC V6P 6T3, Canada.
James MartinsSaNOtize Research & Development Corp, Vancouver, BC V6P 6T3, Canada.
Simon J L TeskeySaNOtize Research & Development Corp, Vancouver, BC V6P 6T3, Canada.ORCID 0000-0002-1231-9292
Jeremy RoadFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A commercially available nitric oxide (NO)-releasing solution (NORS) has demonstrated in vitro efficacy for dermatophytosis, but a NO-releasing gel (NORG) may be more suitable for patient self-application. We present a preliminary investigation of NORS for tinea pedis and an in vitro investigation of NORG for dermatophyte infection, to complement the existing published data and expand support for a possible role of NO formulations in superficial dermatophyte infection. In vitro usage of NORS and NORG is reviewed. The antifungal efficacy of NORG was assessed via time-kill assays, zone of inhibition tests with synthetic dermal membrane permeation, and scanning electron microscopy. A randomized, controlled pilot study of NORS for tinea pedis investigated the safety and efficacy of treatment over three consecutive days, with a day-31 follow-up. The NORG demonstrated rapid fungicidal activity against

Indexed as

antifungal agentdermatophytenitric oxideonychomycosistinea pedistopical therapy

Identifiers

PMID41893160
PMCPMC13028496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.